Table 5.

Posaconazole and concomitant PPI/H2RA use

Concomitant use of PPI or H2RA	Therapeutic (n = 46)	Non-therapeutic (n = 29)	p
Intravenous	(n = 28)	(n = 1)
With PPI/H2RA	27 (96)	1 (100)	1.00
No PPI/H2RA	1 (4)	0
Oral Suspension	(n = 14)	(n = 24)
With PPI/H2RA	6 (43)	22 (92)	<0.01
No PPI/H2RA	8 (57)	2 (8)
Delayed-release tablet	(n = 27)	(n = 6)
With PPI/H2RA	13 (48)	6 (100)	0.03
No PPI/H2RA	14 (52)	0

Data are presented as n (%)